Top-News
  • Depot
  • Watchlist
  • Glocke

  • Innovent Biologics Inc.

    49,7095 $ +3,2795 $ +7,06%
    In : 42,692 € | 10.09.25 19:16:10 Nasdaq OTC Other aktualisieren | Orderbuch | Mehr Kurse »
    ISIN: US45783L1017
    US-Symbol: IVBIY

    Innovent Biologics Inc. News

    15.01.25 - PR Newswire
    Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
    Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer PR Newswire
    05.01.25 - PR Newswire
    Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference
    Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire
    02.01.25 - PR Newswire
    Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration
    Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products ...
    01.01.25 - PR Newswire
    Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
    Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate PR Newswire
    20.12.24 - PR Newswire
    Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration
    Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration PR Newswire
    15.12.24 - PR Newswire
    Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China
    Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China PR Newswire
    08.12.24 - PR Newswire
    Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
    Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024 PR ...

    Newssuche

    Videos

    newspaper
    06.12.25
    Master the Trading!
    In diesem Trading-​Webinar haben wir von A bis Z den Aufbau professionellen Tradings thematisiert und ... Mehr »